Ascierto, Paolo A. http://orcid.org/0000-0002-8322-475X
Casula, Milena
Bulgarelli, Jenny http://orcid.org/0000-0002-6551-0189
Pisano, Marina
Piccinini, Claudia
Piccin, Luisa
Cossu, Antonio
Mandalà, Mario http://orcid.org/0000-0001-8846-8959
Ferrucci, Pier Francesco http://orcid.org/0000-0001-6255-5851
Guidoboni, Massimo http://orcid.org/0000-0001-7703-790X
Rutkowski, Piotr http://orcid.org/0000-0002-8920-5429
Ferraresi, Virginia
Arance, Ana http://orcid.org/0000-0003-2896-1957
Guida, Michele
Maiello, Evaristo
Gogas, Helen
Richtig, Erika
Fierro, Maria Teresa
Lebbe, Celeste http://orcid.org/0000-0002-5854-7290
Helgadottir, Hildur
Queirolo, Paola
Spagnolo, Francesco
Tucci, Marco
Del Vecchio, Michele
Cao, Maria Gonzales http://orcid.org/0000-0003-3791-540X
Minisini, Alessandro Marco
De Placido, Sabino
Sanmamed, Miguel F. http://orcid.org/0000-0002-7295-6074
Mallardo, Domenico http://orcid.org/0000-0002-1081-5313
Paone, Miriam
Vitale, Maria Grazia
Melero, Ignacio http://orcid.org/0000-0002-1360-348X
Grimaldi, Antonio M.
Giannarelli, Diana
Dummer, Reinhard http://orcid.org/0000-0002-2279-6906
Sileni, Vanna Chiarion http://orcid.org/0000-0001-9191-9124
Palmieri, Giuseppe http://orcid.org/0000-0002-4350-2276
Funding for this research was provided by:
This study was supported by unconditioned grants from Bristol-Myers Squibb (Princeton, NJ) and Array Biopharma Inc./Pfizer (Boulder, CO).
Article History
Received: 15 May 2023
Accepted: 14 December 2023
First Online: 2 January 2024
Competing interests
: The authors declare the following competing interests: P.A.A.: Stock and Other Ownership Interests: PrimeVax. Consulting or Advisory Role: Bristol Myers Squibb, Roche/Genentech, Merck Sharp & Dohme, Novartis, Array BioPharma, Merck Serono, Pierre Fabre, Incyte, MedImmune, AstraZeneca, Sun Pharma, Sanofi, Idera, Ultimovacs, Sandoz, Immunocore, 4SC, Alkermes, Italfarmaco, Nektar, Boehringer Ingelheim, Eisai, Regeneron, Daiichi Sankyo, Pfizer, OncoSec, Nouscom, Takis Biotech, Lunaphore Technologies, Seattle Genetics, ITeos Therapeutics, Medicenna, Bio-Al Health, ValoTx. Research Funding: Bristol Myers Squibb (Inst), Roche/Genentech (Inst), Array BioPharma (Inst), Sanofi (Inst), Pfizer (Inst). Travel, Accommodations, Expenses: Merck Sharp & Dohme, Pfizer. M.M. Honoraria: MSD Oncology, Novartis, Pierre Fabre, Sanofi/Aventis, Bristol Myers Squibb/Sanofi. Consulting or Advisory Role: Bristol Myers Squibb, MSD Oncology, Novartis, Pierre Fabre. Research Funding: Novartis (Inst). Pier Francesso Ferrucci. Expert Testimony: Delcath Systems. M.G. Consulting or Advisory Role: BMS, Novartis, Pierre Fabre. Speakers’ Bureau: BMS, Novartis, Pierre Fabre. Research Funding: MSD. P.R. Honoraria: Bristol Myers Squibb, MSD, Novartis, Roche, Pfizer, Pierre Fabre, Sanofi, Merck. Consulting or Advisory Role: Novartis, Blueprint Medicines, Bristol Myers Squibb, Pierre Fabre, MSD, Amgen. Speakers’ Bureau: Pfizer, Novartis, Pierre Fabre. Research Funding: Novartis (Inst), Roche (Inst), Bristol Myers Squibb (Inst). Travel, Accommodations, Expenses: Orphan Europe, Pierre Fabre. V.F. Consulting or Advisory Role: Bristol Myers Squibb, Novartis. Speakers’ Bureau: Bristol Myers Squibb, Novartis, Pierre Fabre, MSD Oncology. A.A. Consulting or Advisory Role: BMS, Roche, Novartis, Pierre Fabre, MSD, Merck, Sanofi. Speakers’ Bureau: Pierre Fabre, Novartis, MSD, BMS, Roche, Merck, Sanofi. Research Funding: Pierre Fabre (Inst), Novartis (Inst), Roche (Inst), BMS (Inst), MSD (Inst), Merck (Inst), Sanofi (Inst). Travel, Accommodations, Expenses: BMS, MSD, Novartis, Pierre Fabre. H.G. Honoraria: Bristol Myers Squibb, MSD Oncology, Pierre Fabre, Sanofi/Regeneron. Consulting or Advisory Role: Bristol Myers Squibb, MSD Oncology, Amgen, Pierre Fabre, Sanofi/Regeneron. Research Funding: Bristol Myers Squibb (Inst), Roche (Inst), MSD Oncology (Inst), Amgen (Inst), Novartis (Inst), Iovance Biotherapeutics (Inst). Travel, Accommodations, Expenses: Bristol Myers Squibb, MSD, Amgen, Pfizer. E.R. Honoraria: Amgen, Bayer, Bristol Myers Squibb, Merck Sharp Dohme, Merck, Novartis, Pierre Fabre, Roche, Sanofi. Consulting or Advisory Role: Amgen, Bayer, Bristol Myers Squibb, Merck Sharp & Dohme, Merck, Novartis, Pierre Fabre. Speakers’ Bureau: Amgen, Bristol Myers Squibb, Merck Sharp & Dohme, Merck, Novartis, Pierre Fabre, Sanofi. Research Funding: Amgen (Inst), Bristol Myers Squibb (Inst), Merck Sharp & Dohme (Inst), Novartis (Inst), Pierre Fabre (Inst), Roche (Inst), Cure. The remaining authors declare no other competing interests.